RCM
CTOR

Radcliffe Capital Management’s Citius Oncology CTOR Stock Holding History

Radcliffe Capital Management’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-226,721
Closed -$2.48M – 96
2023
Q4 		$2.48M Hold
226,721
– – 0.33% 75
2023
Q3 		$2.44M Hold
226,721
– – 0.3% 115
2023
Q2 		$2.39M Sell
226,721
-19,180
-8% -$200K 0.2% 159
2023
Q1 		$2.55M Buy
+245,901
New +$2.53M 0.16% 199

Other funds holding CTOR

WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

Radcliffe Capital Management's CTOR Position: Q1 2024 in Review

Radcliffe Capital Management sold out of Citius Oncology (CTOR) in Q1 2024, closing a stake of 226,721 shares — an estimated $2.48M sold.

Radcliffe Capital Management first reported a position in CTOR in Q1 2023 and held it in 4 quarters. The position peaked at $2.55M in Q1 2023. 15 funds tracked by Wall St. Rank hold CTOR as of Q1 2024.

  • Radcliffe Capital Management reported no remaining Citius Oncology position as of Q1 2024 after selling out during the quarter.
  • Radcliffe Capital Management sold 226,721 Citius Oncology shares in Q1 2024, an estimated $2.48M.
  • Radcliffe Capital Management first reported a position in Citius Oncology in Q1 2023 and held it in 4 quarters.
  • Radcliffe Capital Management's Citius Oncology position peaked at $2.55M in Q1 2023.
  • 15 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2024.

Based on Radcliffe Capital Management's 13F filing for Q1 2024, filed 15 May 2024.